7 results
IDSA Recommendations for Preventing and Managing Microsporidiosis in HIV-AIDS
Preventing Chronic Microsporidiosis:
 • Because chronic microsporidiosis occurs
IDSA Recommendations ... Microsporidiosis #IDSA ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Managing Cryptosporidiosis in HIV-AIDS
Preventing Chronic Cryptosporidiosis:
 • Because chronic cryptosporidiosis occurs
IDSA Recommendations ... Cryptosporidiosis #IDSA ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... Note: Systemic antifungals ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
IDSA Recommendations ... • Antiviral agents ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
Overview of antifungal agents benefits, weaknesses, and adverse effects in the treatment of Coccidioidomycosis.
Fluconazole - Low
Overview of antifungal ... agents benefits ... effects in the treatment ... Coccidioidomycosis #coccidioides ... #table #pharmacology
Antifungal agents benefits, weaknesses, and adverse effects in the treatment of Coccidioidomycosis
Fluconazole
 - Benefits: Low cost/tolerable
Antifungal agents ... effects in the treatment ... #agents #medications ... Coccidioidomycosis #pharmacology ... #coccidioides
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
IDSA Recommendations ... Disease: • CMV end-organ ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology